Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy + Pembrolizumab in Advanced Lung Cancer
NCT06538012Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Aug 2024
- Primary completion
- Sep 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of autologous tumor-infiltrating lymphocytes in lung cancer, sponsored by Essen BioTech. Started Aug 2024; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT06538012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06538012.